US 11,752,103 B2
Tramadol hydrochloride solution
H. Greg Thomas, Carrollton, GA (US); Richard LeVasseur, Oakwood, GA (US); and Jeffrey S. Kiel, Gainesville, GA (US)
Assigned to ATHENA BIOSCIENCE, LLC, Athens, GA (US)
Filed by Athena Bioscience, LLC, Athens, GA (US)
Filed on Jun. 14, 2021, as Appl. No. 17/304,091.
Application 17/304,091 is a continuation of application No. 17/009,565, filed on Sep. 1, 2020, granted, now 11,103,452.
Claims priority of provisional application 62/932,963, filed on Nov. 8, 2019.
Prior Publication US 2021/0299045 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/08 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 31/135 (2006.01)
CPC A61K 9/08 (2013.01) [A61K 9/0053 (2013.01); A61K 31/135 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01)] 12 Claims
 
1. An aqueous oral solution comprising:
(a) from about 4.5 mg/mL to 5.5 mg/mL of tramadol hydrochloride as the sole active ingredient;
(b) propylene glycol;
(c) from about 10% w/v to about 30% w/v of glycerin,
(d) water, and
(e) a sufficient amount of a buffer to maintain the pH of the oral solution from about 4.5 to about 5.5.